Increased KDM2A induces senescence of normal mammary fibroblasts and upregulates programmed death-ligand 1 (PD-L1) expression in a p53-dependent manner, both in vitro and in vivo, promoting mammary tumor growth. Here, KDM2A is linked to breast cancer.